Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
Open/View files
Date
2015
Author(s)
Powderly, John
Szmulewitz, Russell Z
Ribas, Antoni
Weber, Jeffrey
Loo, Deryk
Baughman, Jan
Chen, Francine
Moore, Paul
Bonvini, Ezio
Vasselli, James
Wigginton, Jon
Cohen, Roger
Burris, Howard
Chmielowski, Bartosz
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Powderly, J., G. Cote, K. Flaherty, R. Z. Szmulewitz, A. Ribas, J. Weber, D. Loo, et al. 2015. “Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3.” Journal for Immunotherapy of Cancer 3 (Suppl 2): O8. doi:10.1186/2051-1426-3-S2-O8. http://dx.doi.org/10.1186/2051-1426-3-S2-O8.
Other Available Sources
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
Collection